• Operating cash flow of NZ$2.1 million
• Strong cash receipts of NZ$23.5 million
• Positive net cash flow for fourth consecutive quarter
• FY26 guidance reaffirmed - revenue of NZ$92-100 million, EBITDA of NZ$5-8 million

Aroa Biosurgery Limited (ASX: ARX) has reported a strong September 2025 quarter, with operating cash flow of NZ$2.1 million and strong cash receipts from customers of NZ$23.5 million. The company posted its fourth consecutive quarter of positive net cash flow, with total cash on hand increasing by NZ$1.3 million to end the quarter with NZ$23.4 million. The company remains debt-free. Aroa reaffirmed its full-year FY26 guidance, with total revenue expected to be in the range of NZ$92-100 million (growth of 10-20% on FY25) and normalised EBITDA of NZ$5-8 million (growth of 19-90% on FY25). The company continues to see strong sales of its high-margin Myriad product family, achieving its highest quarter on record with NZ$10.2 million in sales. Aroa also strengthened its clinical evidence during the quarter, with eight new peer-reviewed studies published, including a book chapter highlighting the unique attributes of its AROA ECM technology. The company noted that proposed changes to US outpatient wound care reimbursement policy present an opportunity for its Symphony product. Aroa will host an investor event in Sydney following the announcement of its H1 FY26 results on 25 November 2025.

FY26 total revenue of NZ$92-100 million (growth of 10-20% on FY25) and normalised EBITDA of NZ$5-8 million (growth of 19-90% on FY25).